<DOC>
	<DOCNO>NCT00484679</DOCNO>
	<brief_summary>The purpose study see whether treat alopecia areata injection corticosteroid , Triamcinolone acetonide 10mg/cc ( Kenalog-10 ) , impact adrenal gland .</brief_summary>
	<brief_title>Adrenal Function Use Intralesional Triamcinolone Acetonide 10 mg/mL ( Kenalog-10 ) Patients With Alopecia Areata</brief_title>
	<detailed_description>1 . To determine effect intralesional Triamcinolone Acetonide 10mg/cc ( Kenalog 10 ) use treatment alopecia areata adrenal function . 2 . To evaluate efficacy intralesional corticosteroid ( Kenalog-10 ) hair regrowth moderate severe alopecia areata . 18 subject moderate severe alopecia areata enrol 15 subject complete study visit . Subjects underwent intralesional triamcinolone acetonide ( 10mg/cc ) ( Kenalog-10 ) injection every 6 week period 6 month General Clinical Research Center ( GCRC ) . This period follow 6 week , injection-free , safety follow-up visit . Adrenal function assess utilization Low Dose Adrenocorticotropic Hormone Stimulation Test ( ACTH ) measure adrenal gland production cortisol exogenously administer ACTH . Serum blood draw 3 mL do baseline 6-week interval start schedule appointment intralesional treatment approximately 0800 hour . Two blood draw take time 0 30 minute 1 mcg bolus dose synthetic ACTH ( Cortrosyn ) . Patients underwent scheduled course intralesional corticosteroid ( Kenalog-10 ) injection study data collect , SALT score physician assessment AA , time blood draw .</detailed_description>
	<mesh_term>Alopecia</mesh_term>
	<mesh_term>Alopecia Areata</mesh_term>
	<mesh_term>Triamcinolone hexacetonide</mesh_term>
	<mesh_term>Triamcinolone Acetonide</mesh_term>
	<mesh_term>Triamcinolone</mesh_term>
	<mesh_term>Triamcinolone diacetate</mesh_term>
	<criteria>Subject clinical diagnosis alopecia areata . Written inform consent HIPAA authorization obtain . Female subject childbearing potential negative pregnancy test agree use acceptable method birth control prevent pregnancy . In opinion investigator , subject candidate intralesional therapy alopecia areata . Subject agree comply protocol requirement attend require study visit consider good study subject . Subject meet concomitant medication washout requirement . Subject &gt; /= 18 year age . Subject alopecia universalis . Subject known adrenocortical insufficiency Cushing 's Syndrome . Subject pregnant lactating . Subject current control uncontrolled bacterial , viral , fungal , atypical , opportunistic infection . Subject possess hypersensitivity cortrosyn Triamcinolone Acetonide ( Kenalog10 ) component formulation . Subject currently undergo therapy malignancy within past five year . Subject history substance abuse within past five year . Subject use oral corticosteroid within past 12 month . Subject concurrent use phenytion rifampin , phenobarbital , mitotane , formulation corticosteroid medication . Subject medical condition , judgement investigator , would jeopardize subject 's safety follow exposure administer medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>